BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition
BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its strategy…
News
Wes Streeting: £29bn NHS boost ‘substantial’ but reform still needed
Vaccine sceptics among new members hired by RFK Jr for CDC’s vaccine panel
Enterome to advance EO2463 immunotherapy with $19m funding
Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs
FDA approves Capsida’s CAP-003 gene therapy for Parkinson’s
SpliceBio secures $135m for gene therapy development
Gilead hit with FDA clinical hold for batch of HIV trials
